EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies

ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced clinical results from two studies of VBLOC® vagal blocking therapy, including additional data from its EMPOWER™ study in obesity and interim clinical results from its ongoing VBLOC-DM2 ENABLE (DM2) study in diabetes using the next-generation rechargeable (RC) device. For all studies, the Maestro® System continues to meet its safety goals, with no therapy-related serious adverse events reported across the various study populations.